Ed Arce
Stock Analyst at WestPark Capital
(3.77)
# 700
Out of 5,148 analysts
376
Total ratings
46.04%
Success rate
9.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $24 → $28 | $14.51 | +92.97% | 13 | Sep 30, 2025 | |
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $29.53 | +1.59% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $132 | $1.53 | +8,527.45% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $6.99 | +972.96% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $8.35 | +618.56% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $1.26 | +495.24% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $6.29 | +106.68% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $3.07 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.91 | +558.04% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $6.97 | +905.03% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $29.68 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $1.53 | +15,586.27% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.27 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $5.72 | +459.44% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $90.09 | -20.08% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $435.62 | -7.03% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.47 | -14.99% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $23.02 | +312.68% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $4.67 | +7.07% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $32.83 | +46.21% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $42.03 | -82.16% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.28 | +1,670.54% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $14.21 | -8.52% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $40.42 | -38.15% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.62 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.19 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $33.34 | -79.00% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $41.60 | -49.52% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.87 | - | 2 | Feb 15, 2017 |
Enanta Pharmaceuticals
Sep 30, 2025
Maintains: Buy
Price Target: $24 → $28
Current: $14.51
Upside: +92.97%
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $29.53
Upside: +1.59%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $132
Current: $1.53
Upside: +8,527.45%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $6.99
Upside: +972.96%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $8.35
Upside: +618.56%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $1.26
Upside: +495.24%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $6.29
Upside: +106.68%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $3.07
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.91
Upside: +558.04%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $6.97
Upside: +905.03%
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $29.68
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $1.53
Upside: +15,586.27%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $5.72
Upside: +459.44%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $90.09
Upside: -20.08%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $435.62
Upside: -7.03%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.47
Upside: -14.99%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $23.02
Upside: +312.68%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $4.67
Upside: +7.07%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $32.83
Upside: +46.21%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $42.03
Upside: -82.16%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.28
Upside: +1,670.54%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $14.21
Upside: -8.52%
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $40.42
Upside: -38.15%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.62
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.19
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $33.34
Upside: -79.00%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $41.60
Upside: -49.52%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $4.87
Upside: -